Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856

Role of trace amine‑associated receptor 1 in the medial prefrontal cortex in chronic social stress-induced cognitive deficits in mice

(2021) Yue Zhang et al.   PHARMACOLOGICAL RESEARCH

Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine

(2020) Michelle Kokkinou et al.   MOLECULAR PSYCHIATRY

A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

(2020) Kenneth S. Koblan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic treatment with the antipsychotic drug blonanserin modulates the responsiveness to acute stress with anatomical selectivity

(2020) Francesca Marchisella et al.   PSYCHOPHARMACOLOGY

Anti-stress Properties of Atypical Antipsychotics

(2020) Alice Sanson et al.   Pharmaceuticals

Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms

(2019) Robert A. McCutcheon et al.   TRENDS IN NEUROSCIENCES

SEP-363856, A NOVEL PSYCHOTROPIC AGENT WITH A UNIQUE, NON-D2 RECEPTOR MECHANISM OF ACTION

(2019) Nina Dedic et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review

(2018) Ragy R. Girgis et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Role of trace amine-associated receptor 1 in nicotine’s behavioral and neurochemical effects

(2018) Jian-Feng Liu et al.   NEUROPSYCHOPHARMACOLOGY

Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences

(2018) Stefano Aringhieri et al.   PHARMACOLOGY & THERAPEUTICS

Arc protein: a flexible hub for synaptic plasticity and cognition

(2018) Oleksii Nikolaienko et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

5-HT1A parital agonism and 5-HT7 antagonism restore episodic memory in subchronic phencyclidine-treated mice: role of brain glutamate, dopamine, acetylcholine and GABA

(2018) Mei Huang et al.   PSYCHOPHARMACOLOGY

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2018) Spencer L James et al.   LANCET

NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update

(2017) Daniela Cadinu et al.   NEUROPHARMACOLOGY

Daily exposure to a touchscreen-paradigm and associated food restriction evokes an increase in adrenocortical and neural activity in mice

(2016) Anne Stephanie Mallien et al.   HORMONES AND BEHAVIOR

Schizophrenia

(2016) Michael J Owen et al.   LANCET

Acute phencyclidine administration induces c-Fos-immunoreactivity in interneurons in cortical and subcortical regions

(2016) Mona E. Hervig et al.   NEUROSCIENCE

Lurasidone Exerts Antidepressant Properties in the Chronic Mild Stress Model through the Regulation of Synaptic and Neuroplastic Mechanisms in the Rat Prefrontal Cortex

(2015) Alessia Luoni et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Npas4 Regulates Excitatory-Inhibitory Balance within Neural Circuits through Cell-Type-Specific Gene Programs

(2014) Ivo Spiegel et al.   CELL

New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways

(2014) Daniel Lodge et al.   Drug Design Development and Therapy

Amphetamine, past and present – a pharmacological and clinical perspective

(2013) David J Heal et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The activity-dependent transcription factor NPAS4 regulates domain-specific inhibition

(2013) Brenda L. Bloodgood et al.   NATURE

Repeated aripiprazole treatment regulates Bdnf, Arc and Npas4 expression under basal condition as well as after an acute swim stress in the rat brain

(2013) Alessia Luoni et al.   PHARMACOLOGICAL RESEARCH

Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment

(2013) Alessia Luoni et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Rethinking 5-HT1A Receptors: Emerging Modes of Inhibitory Feedback of Relevance to Emotion-Related Behavior

(2012) Stefanie C. Altieri et al.   ACS Chemical Neuroscience

TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity

(2011) F. G. Revel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Task-Dependent Changes in Short-Term Memory in the Prefrontal Cortex

(2010) M. R. Warden et al.   JOURNAL OF NEUROSCIENCE

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism

(2010) Joanna C. Neill et al.   PHARMACOLOGY & THERAPEUTICS

F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist and 5-HT1A receptor agonist properties: Influence on immediate-early gene expression in rat prefrontal cortex and striatum

(2009) Liesbeth A. Bruins Slot et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effects of subchronic phencyclidine on behaviour of female rats on the elevated plus maze and open field

(2009) SL McLean et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN

The Immediate Early Gene Arc/Arg3.1: Regulation, Mechanisms, and Function

(2008) C. R. Bramham et al.   JOURNAL OF NEUROSCIENCE

Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague–Dawley rats: A locomotor activity and gene induction study

(2007) Mikhail Kalinichev et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY